Activation of human dendritic cells by recombinant modified vaccinia virus ankara vectors encoding survivin and IL-2 genes in vitro

Human Gene Therapy

Volumn 21, Issue 1, 2010, Pages 98-108

  Tao, Ran ^a   Li, Lian ^a   Huang, Wenlin ^b   Zheng, Limin ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA VECTOR; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CD3+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL STRAIN BHK; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; T LYMPHOCYTE; VACCINIA VIRUS; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; ANTIGEN PRESENTATION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICROTUBULE-ASSOCIATED PROTEINS; PHENOTYPE; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; VACCINIA VIRUS;

VACCINIA VIRUS ANKARA;

EID: 74949084669     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.113     Document Type: Article

References (48)

1. Acres, B. (2007). Cancer immunotherapy: Phase II clinical studies with TG4010 (MVA-MUC1-IL2). J. BUON 12 Suppl 1, S71-S75.
2. Amato, R.J. (2007). 5T4-modified vaccinia Ankara: Progress in tumor-associated antigen-based immunotherapy. Exp. Opin. Biol. Ther. 7, 1463-1469.
3. Behboudi, S., Moore, A., Gilbert, S.C., Nicoll, C.L., and Hill, A.V. (2004). Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction. Vaccine 22, 4326-4331.
4. Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M., and Koup, R.A. (2003). Sensitive and viable identification of antigen-specific CD8\+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281, 65-78.
5. Broder, C.C., and Earl, P.L. (1997). Design and construction of recombinant vaccinia viruses. Methods Mol. Biol. 62, 173-197.
6. Bronte, V., Carroll, M.W., Goletz, T.J., Wang, M., Overwijk, W.W., Marincola, F., Rosenberg, S.A., Moss, B., and Restifo, N.P. (1997). Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. U.S.A. 94, 3183-3188.
7. Cebere, I., Dorrell, L., McShane, H., Simmons, A., McCormack, S., Schmidt, C., Smith, C., Brooks, M., Roberts, J.E., Darwin, S.C., Fast, P.E., Conlon, C., Rowland-Jones, S., McMichael, A.J., and Hanke, T. (2006). Phase I clinical trial safety of DNA-and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24, 417-425.
8. Chahroudi, A., Garber, D.A., Reeves, P., Liu, L., Kalman, D., and Feinberg, M.B. (2006). Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J. Virol. 80, 8469-8481.
9. Chakrabarti, S., Sisler, J.R., and Moss, B. (1997). Compact, synthetic, vaccinia virus early=late promoter for protein expression. BioTechniques 23, 1094-1097.
10. Drexler, I., Staib, C., and Sutter, G. (2004). Modified vaccinia virus Ankara as antigen delivery system: How can we best use its potential? Curr. Opin. Biotechnol. 15, 506-512.
11. Drillien, R., Spehner, D., Bohbot, A., and Hanau, D. (2000). Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology 268, 471-481.
12. Drillien, R., Spehner, D., and Hanau, D. (2004). Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J. Gen. Virol. 85, 2167-2175.
13. Engelmayer, J., Larsson, M., Subklewe, M., Chahroudi, A., Cox, W.I., Steinman, R.M., and Bhardwaj, N. (1999). Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion. J. Immunol. 163, 6762-6768.
14. Gasteiger, G., Kastenmuller, W., Ljapoci, R., Sutter, G., and Drexler, I. (2007). Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J. Virol. 81, 11925-11936.
15. Gomez, C.E., Najera, J.L., Krupa, M., and Esteban, M. (2008). The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8, 97-120.
16. Granucci, F., Andrews, D.M., Degli-Esposti, M.A., and Ricciardi-Castagnoli, P. (2002). IL-2 mediates adjuvant effect of dendritic cells. Trends Immunol. 23, 169-171.
17. Harrer, E., Bauerle, M., Ferstl, B., Chaplin, P., Petzold, B., Mateo, L., Handley, A., Tzatzaris, M., Vollmar, J., Bergmann, S., Rittmaier, M., Eismann, K., Muller, S., Kalden, J.R., Spriewald, B., Willbold, D., and Harrer, T. (2005). Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: Safety, immunogenicity and influence on viral load during treatment interruption. Antivir. Ther. 10, 285-300.
18. Harris, K.M., Lenz, P., Hankey, K.G., MacVittie, T., Farese, A., Nakajima, K., Hasumi, K., and Mann, D.L. (2008). Products of anti-CD3=anti-CD28 activated lymphocytes induce differentiation and maturation of dendritic cells and have adjuvant-like activity in vitro and in vivo. Clin. Immunol. 129, 58-68.
19. He, T.C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W., and Vo-gelstein, B. (1998). A simplified system for generating recom-binant adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509-2514.
20. Heckman, K.L., and Pease, L.R. (2007). Gene splicing and mu-tagenesis by PCR-driven overlap extension. Nat. Protoc. 2, 924-932.
21. Hodge, J.W., Poole, D.J., Aarts, W.M., Gomez Yafal, A., Gritz, L., and Schlom, J. (2003). Modified vaccinia virus Ankara re-combinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 63, 7942-7949.
22. Idenoue, S., Hirohashi, Y., Torigoe, T., Sato, Y., Tamura, Y., Hariu, H., Yamamoto, M., Kurotaki, T., Tsuruma, T., Asanu-ma, H., Kanaseki, T., Ikeda, H., Kashiwagi, K., Okazaki, M., Sasaki, K., Sato, T., Ohmura, T., Hata, F., Yamaguchi, K., Hirata, K., and Sato, N. (2005). A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin. Cancer Res. 11, 1474-1482.
23. Jenne, L., Hauser, C., Arrighi, J.F., Saurat, J.H., and Hugin, A.W. (2000). Poxvirus as a vector to transduce human dendritic cells for immunotherapy: Abortive infection but reduced APC function. Gene Ther. 7, 1575-1583.
24. Kastenmuller, W., Drexler, I., Ludwig, H., Erfle, V., Peschel, C., Bernhard, H., and Sutter, G.(2006). Infection ofhuman dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology 350, 276-288.
25. Kato, J., Kuwabara, Y., Mitani, M., Shinoda, N., Sato, A., Toya-ma, T., Mitsui, A., Nishiwaki, T., Moriyama, S., Kudo, J., and Fujii, Y. (2001). Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int. J. Cancer 95, 92-95.
26. Kuang, D.M., Wu, Y., Chen, N., Cheng, J., Zhuang, S.M., and Zheng, L. (2007). Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 110, 587-595.
27. Kuang, D.M., Zhao, Q., Xu, J., Yun, J.P., Wu, C., and Zheng, L. (2008). Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent pathways. J. Immunol. 181, 3089-3098.
28. Lanzavecchia, A., and Sallusto, F. (2004). Lead and follow: The dance of the dendritic cell and T cell. Nat. Immunol. 5, 1201-1202.
29. Liu, L., Chavan, R., and Feinberg, M.B. (2008). Dendritic cells are preferentially targeted among hematolymphocytes by modified vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 9, 15.
30. Liu, M., Acres, B., Balloul, J.M., Bizouarne, N., Paul, S., Slos, P., and Squiban, P. (2004). Gene-based vaccines and immuno-therapeutics. Proc. Natl. Acad. Sci. U.S.A. 101 Suppl 2, 14567-14571.
31. McCurdy, L.H., Larkin, B.D., Martin, J.E., and Graham, B.S. (2004). Modified vaccinia Ankara: Potential as an alternative smallpox vaccine. Clin. Infect. Dis. 38, 1749-1753.
32. Moss, B. (1991). Vaccinia virus: A tool for research and vaccine development. Science 252, 1662-1667.
33. Mukherjee, S., Upham, J.W., Ramshaw, I., Bundell, C., van Bruggen, I., Robinson, B.W., and Nelson, D.J. (2003). Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cyto-kine IL-12. Cancer Gene Ther. 10, 591-602.
34. Nemeckova, S., Sroller, V., Hainz, P., Krystofova, J., Smahel, M., and Kutinova, L. (2003). Experimental therapy of HPV16 induced tumors with IL12 expressed by recombinant vaccinia virus in mice. Int. J. Mol. Med. 12, 789-796.
35. Pastoret, P.P., and Vanderplasschen, A. (2003). Poxviruses as vaccine vectors. Comp. Immunol. Microbiol. Infect. Dis. 26, 343-355.
36. Pennati, M., Folini, M., and Zaffaroni, N. (2007). Targeting sur-vivin in cancer therapy: Fulfilled promises and open questions. Carcinogenesis 28, 1133-1139.
37. Perez-Jimenez, E., Kochan, G., Gherardi, M.M., and Esteban, M. (2006). MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect. 8, 810-822.
38. Qiao, L., Xu, Z., Zhao, T., Zhao, Z., Shi, M., Zhao, R.C., Ye, L., and Zhang, X. (2008). Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 18, 500-507.
39. Ramsey-Ewing, A., and Moss, B. (1998). Apoptosis induced by a postbinding step of vaccinia virus entry into Chinese hamster ovary cells. Virology 242, 138-149.
40. Shen, Y., and Nemunaitis, J. (2005). Fighting cancer with vaccinia virus: Teaching new tricks to an old dog. Mol. Ther. 11, 180-195.
41. Smith, C.L., Dunbar, P.R., Mirza, F., Palmowski, M.J., Shepherd, D., Gilbert, S.C., Coulie, P., Schneider, J., Hoffman, E., Hawkins, R., Harris, A.L., and Cerundolo, V. (2005). Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer 113, 259-266.
42. Steinbrink, K., Jonuleit, H., Muller, G., Schuler, G., Knop, J., and Enk, A.H. (1999). Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(\+) T cells resulting in a failure to lyse tumor cells. Blood 93, 1634-1642.
43. Sutter, G., and Moss, B. (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U.S.A. 89, 10847-10851.
44. Trevor, K.T., Hersh, E.M., Brailey, J., Balloul, J.M., and Acres, B. (2001). Transduction of human dendritic cells with a recom-binant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol. Immunother. 50, 397-407.
45. Voskoboinik, I., Smyth, M.J., and Trapani, J.A. (2006). Perforin-mediated target-cell death and immune homeostasis. Nat. Rev. 6, 940-952.
46. Vulink, A., Radford, K.J., Melief, C., and Hart, D.N. (2008). Dendritic cells in cancer immunotherapy. Adv. Cancer Res. 99, 363-407.
47. Wang, Z., Zhou, W., Srivastava, T., La Rosa, C., Mandarino, A., Forman, S.J., Zaia, J.A., Britt, W.J., and Diamond, D.J. (2008). A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology 377, 379-390.
48. Yates, N.L., Yammani, R.D., and Alexander-Miller, M.A. (2008). Dose-dependent lymphocyte apoptosis following respiratory infection with vaccinia virus. Virus Res. 137, 198-205.